Related references
Note: Only part of the references are listed.A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis
Mickael Hiligsmann et al.
PHARMACOECONOMICS (2015)
Use of strontium ranelate and risk of acute coronary syndrome: cohort study
Henrik Svanstrom et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Cardiac concerns associated with strontium ranelate
Jean-Yves Reginster
EXPERT OPINION ON DRUG SAFETY (2014)
Hypertension management in England: a serial cross-sectional study from 1994 to 2011
Emanuela Falaschetti et al.
LANCET (2014)
Strontium ranelate lives to fight another day
Juliet Compston
MATURITAS (2014)
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis
M. Tadrous et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD
C. Cooper et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate
B. Abrahamsen et al.
OSTEOPOROSIS INTERNATIONAL (2014)
A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years
M. Audran et al.
RHEUMATOLOGY INTERNATIONAL (2013)
SCOPE: a scorecard for osteoporosis in Europe
J. A. Kanis et al.
ARCHIVES OF OSTEOPOROSIS (2013)
Treatment of osteoporosis in women intolerant of oral bisphosphonates
Terry J. Aspray et al.
MATURITAS (2012)
Partial adherence: a new perspective on health economic assessment in osteoporosis
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years
Mickael Hiligsmann et al.
BONE (2010)
Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women
M. Hiligsmann et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women
V. Rabenda et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Persistence with bisphosphonate treatment for osteoporosis: Finding the root of the problem
JA Cramer et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study
JY Reginster et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis
PJ Meunier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
